Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 121

2.

Generation of tumor-specific T lymphocytes using dendritic cell/tumor fusions and anti-CD3/CD28.

Rosenblatt J, Wu Z, Vasir B, Zarwan C, Stone R, Mills H, Friedman T, Konstantinopoulos PA, Spentzos D, Ghebremichael M, Stevenson K, Neuberg D, Levine JD, Joyce R, Tzachanis D, Boussiotis V, Kufe D, Avigan D.

J Immunother. 2010 Feb-Mar;33(2):155-66. doi: 10.1097/CJI.0b013e3181bed253.

3.

Nonantigen specific CD8+ T suppressor lymphocytes originate from CD8+CD28- T cells and inhibit both T-cell proliferation and CTL function.

Filaci G, Fravega M, Negrini S, Procopio F, Fenoglio D, Rizzi M, Brenci S, Contini P, Olive D, Ghio M, Setti M, Accolla RS, Puppo F, Indiveri F.

Hum Immunol. 2004 Feb;65(2):142-56.

PMID:
14969769
4.

Comparative analysis of dendritic cells and anti-CD3/CD28 expanded regulatory T cells for application in transplantation.

Zeng M, Guinet E, Nouri-Shirazi M.

Transpl Immunol. 2009 Dec;22(1-2):82-92. doi: 10.1016/j.trim.2009.07.004. Epub 2009 Jul 25.

PMID:
19635560
5.

Dendritic cells partially abrogate the regulatory activity of CD4+CD25+ T cells present in the human peripheral blood.

Ahn JS, Krishnadas DK, Agrawal B.

Int Immunol. 2007 Mar;19(3):227-37. Epub 2007 Feb 7.

PMID:
17289657
6.
7.

Simultaneous targeting of CD3 on T cells and CD40 on B or dendritic cells augments the antitumor reactivity of tumor-primed lymph node cells.

Li Q, Grover AC, Donald EJ, Carr A, Yu J, Whitfield J, Nelson M, Takeshita N, Chang AE.

J Immunol. 2005 Aug 1;175(3):1424-32.

8.

Dominant role of antigen dose in CD4+Foxp3+ regulatory T cell induction and expansion.

Turner MS, Kane LP, Morel PA.

J Immunol. 2009 Oct 15;183(8):4895-903. doi: 10.4049/jimmunol.0901459.

9.

In vitro stimulation and expansion of human tumour-reactive CD8+ cytotoxic T lymphocytes by anti-CD3/CD28/CD137 magnetic beads.

Teschner D, Wenzel G, Distler E, Schnürer E, Theobald M, Neurauter AA, Schjetne K, Herr W.

Scand J Immunol. 2011 Aug;74(2):155-64. doi: 10.1111/j.1365-3083.2011.02564.x.

10.
11.

Products of anti-CD3/anti-CD28 activated lymphocytes induce differentiation and maturation of dendritic cells and have adjuvant-like activity in vitro and in vivo.

Harris KM, Lenz P, Hankey KG, MacVittie T, Farese A, Nakajima K, Hasumi K, Mann DL.

Clin Immunol. 2008 Oct;129(1):58-68. doi: 10.1016/j.clim.2008.06.003. Epub 2008 Aug 8.

PMID:
18691939
12.

Immature dendritic cells convert anergic nonregulatory T cells into Foxp3- IL-10+ regulatory T cells by engaging CD28 and CTLA-4.

Pletinckx K, Vaeth M, Schneider T, Beyersdorf N, Hünig T, Berberich-Siebelt F, Lutz MB.

Eur J Immunol. 2015 Feb;45(2):480-91. doi: 10.1002/eji.201444991. Epub 2014 Dec 2.

13.

Synergistic effects of IL-12 and IL-18 in skewing tumor-reactive T-cell responses towards a type 1 pattern.

Li Q, Carr AL, Donald EJ, Skitzki JJ, Okuyama R, Stoolman LM, Chang AE.

Cancer Res. 2005 Feb 1;65(3):1063-70.

14.

Streptococcal preparation OK-432 promotes fusion efficiency and enhances induction of antigen-specific CTL by fusions of dendritic cells and colorectal cancer cells.

Koido S, Hara E, Homma S, Torii A, Mitsunaga M, Yanagisawa S, Toyama Y, Kawahara H, Watanabe M, Yoshida S, Kobayashi S, Yanaga K, Fujise K, Tajiri H.

J Immunol. 2007 Jan 1;178(1):613-22.

15.

Activation of antitumor cytotoxic T lymphocytes by fusions of human dendritic cells and breast carcinoma cells.

Gong J, Avigan D, Chen D, Wu Z, Koido S, Kashiwaba M, Kufe D.

Proc Natl Acad Sci U S A. 2000 Mar 14;97(6):2715-8. Erratum in: Proc Natl Acad Sci U S A 2000 Apr 25;97(9):5011.

16.

CD4(+) T-cell activation is differentially modulated by bacteria-primed dendritic cells, but is generally down-regulated by n-3 polyunsaturated fatty acids.

Brix S, Lund P, Kjaer TM, Straarup EM, Hellgren LI, Frøkiaer H.

Immunology. 2010 Mar;129(3):338-50. doi: 10.1111/j.1365-2567.2009.03163.x. Epub 2009 Nov 11.

17.

Plasmacytoid dendritic cells are inefficient in activation of human regulatory T cells.

Hubo M, Jonuleit H.

PLoS One. 2012;7(8):e44056. doi: 10.1371/journal.pone.0044056. Epub 2012 Aug 29.

18.
19.

Sequential induction of effector function, tissue migration and cell death during polyclonal activation of mouse regulatory T-cells.

Langenhorst D, Gogishvili T, Ribechini E, Kneitz S, McPherson K, Lutz MB, Hünig T.

PLoS One. 2012;7(11):e50080. doi: 10.1371/journal.pone.0050080. Epub 2012 Nov 30.

20.

HOZOTs, novel human regulatory T-cell lines, exhibit helper or suppressor activities depending on dendritic cell or anti-CD3 stimulation.

Sugimoto A, Suzuki M, Otani T, Okochi A, Takeuchi M, Yamasaki F, Nakamura S, Kibata M.

Exp Hematol. 2009 Dec;37(12):1454-63. doi: 10.1016/j.exphem.2009.10.002. Epub 2009 Oct 9.

PMID:
19819295

Supplemental Content

Support Center